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MIC results for 115 Staphylococcus intermedius group isolates are presented. Of these, 33% were methicillin resistant, among
which 51.4%were susceptible to doxycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole. All of the
isolates were susceptible to ceftaroline, daptomycin, linezolid, nitrofurantoin, quinupristin-dalfopristin, rifampin, tigecycline,
and vancomycin. Of all the isolates, 82.6%, 67.8%, and 23.5%were susceptible to ciprofloxacin, erythromycin, and penicillin,
respectively. No isolates harboredmupA or qacA/B genes, which suggested a lack of resistance to mupirocin or chlorhexidine.
The Staphylococcus intermedius group (SIG) is comprised ofStaphylococcus intermedius, Staphylococcus pseudintermedius,
and Staphylococcus delphini. These Gram-positive cocci (except
for S. intermedius) are positive for tube coagulase and negative for
slide coagulase and may be misidentified as Staphylococcus aureus
by clinical laboratories that test human specimens (1). A colonizer
of the nares and anal mucosa of cats and dogs, S. pseudintermedius
is increasingly being recognized in human diagnostic specimens
(2). This may be due in part to improved diagnostic technologies,
such as matrix-assisted laser desorption ionization–time of flight
mass spectrometry (MALDI-TOF MS), now being used in many
clinical laboratories. S. pseudintermedius has been documented to
cause invasive infections, including brain abscesses, endocarditis,
and bacteremia, in humans (3). Methicillin resistance among S.
pseudintermedius isolated fromdogs is increasing (4), with rates of
up to 47% in some regions of the world (5). This resistance is
predominantly due to the dissemination of the ST71 clonal lineage
in Europe and the ST68 clonal lineage in North America (4). Me-
thicillin-resistant isolates often display resistance to other classes
of antimicrobials used in veterinary medicine, including amin-
oglycosides, fluoroquinolones, lincosamides, macrolides, and tet-
racyclines, and to chloramphenicol and trimethoprim-sulfame-
thoxazole (SXT) (6). However, limited susceptibility data are
available for S. pseudintermedius with antimicrobials used for hu-
mans. We recently conducted a study to evaluate oxacillin and
cefoxitin disk and MIC results as predictors of methicillin resis-
tance (encoded by mecA) in a collection of 115 SIG isolates from
human and veterinary specimens associated with clinical infec-
tions. This study documented that cefoxitin testing, which is rec-
ommended by the Clinical and Laboratories Standards Institute
(CLSI) to predict methicillin resistance for other species of staph-
ylococci, is a poor predictor ofmecA in SIG,whereas both oxacillin
disk and MIC tests accurately detect mecA-mediated oxacillin re-
sistance in these isolates (7). As a result of our study, CLSI pub-
lished S. pseudintermedius-specific oxacillin breakpoints in the
26th edition of the M100S standard (8). In the present study, we
document the results of antimicrobial susceptibility testing (AST)
for this collection of 115 SIG isolates, including 111 isolates of S.
pseudintermedius (45 from human, 56 from canine, 7 from feline,
2 from avian, and 1 from porcine sources) and 4 isolates of S.
delphini (3 from equine and 1 from avian sources).
Bacterial isolates were described in our previous article (7).
AST was performed according to the CLSI reference broth mi-
crodilution (BMD) MIC method (8), using panels prepared in-
house with cation-adjusted Mueller-Hinton broth (MHB). MHB
was supplemented with 50 mg/liter CaCl2 for daptomycin testing
and 2%NaCl for oxacillin testing (9). Fifteen antimicrobial agents
were tested (Table 1). BMD tests were read after 16 to 20 h of
incubation at 35°C in ambient air for all of the antimicrobials
except oxacillin and vancomycin, where the final reading was
done after 24 h of incubation. MIC results were interpreted ac-
cording to the Staphylococcus spp. breakpoints listed in CLSI
M100S, 26th edition, including use of the new oxacillin S. pseud-
intermedius breakpoints and ceftaroline and vancomycin break-
points for S. aureus (8). Because there are no CLSI tigecycline
breakpoints, the Food and Drug Administration (FDA) break-
point for S. aureus was used. All isolates with penicillin-suscepti-
ble MICs (0.12 g/ml) were tested by penicillin disk diffusion
using the standard CLSI method and examined for -lactamase
production using a BBL Cefinase disk (BD, Sparks, MD). In addi-
tion to taking zone measurements, the zone edges were evaluated
for sharp versus fuzzy borders around the penicillin disks. -Lac-
tamase testing was performed using growth taken from the zone
margin surrounding a penicillin disk test on BBLMueller-Hinton
agar (MHA) (BD) after 16 to 18 h of incubation. mecA PCR and
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SCCmec typing were performed as described in our previous arti-
cle (7). Mupirocin resistance was determined by PCR for the
mupA gene, and chlorhexidine resistance was determined by PCR
for the qacA/B gene, as described elsewhere (10).
MIC results obtained for the 115 isolates are shown in Table 1.
Thirty-seven isolates (32.2%), 4 of human origin and 33 of veter-
inary origin, harbored the mecA gene. Using CLSI M100S Staph-
ylococcus spp. interpretive criteria, 33 (42.3%) of the 78 mecA-
negative isolates had penicillin-susceptible MICs of0.12 g/ml
(Table 1). For 27 of 33 isolates,MICswere0.06g/ml, penicillin
zone measurements were susceptible at 29 mm, and induced
nitrocefin tests were negative. Six (18.2%) of 33 isolates, 5 human
and 1 animal isolate, yielded a positive induced nitrocefin test,
indicating the presence of a -lactamase. Six isolates demon-
strated penicillin zones of28 mm (resistant), and all had sharp
zone edges. Five of these isolates had penicillin MICs of 0.12 g/
ml, and 1 isolate had a penicillin MIC of 0.03 g/ml. Repeat
testing in two laboratories confirmed the results. When the nitro-
cefin tests were performed using uninduced colonies (i.e., not
from a penicillin zone margin), variable results were obtained,
with 0 to 4 of the 6 isolates yielding a positive result in different
laboratories on different days, when testing colonies grown on
blood agar plates or on MHA. As such, a test for -lactamase
production should be performed for all penicillin-susceptible S.
pseudintermedius isolates, as done for other Staphylococcus spp.
Whether a penicillin zone edge test is sufficient for this purpose or
an induced nitrocefin-based test is needed remains to be deter-
mined. However, in our limited analysis, the penicillin zone edge
test was 100% concordant with the nitrocefin results obtained
when testing induced colonies. All isolates were susceptible to cef-
taroline, the cephalosporin with high-affinity binding to PBP 2a
expressed by mecA.
With regard to the non- -lactam agents, significant differ-
ences were noted in the percentage ofmethicillin-resistant isolates
susceptible to doxycycline, SXT, and clindamycin, compared to
what has been documented with contemporary isolates of S. au-
reus (11). This constellation of multidrug resistance is consistent
with the multidrug-resistant (MDR) S. pseudintermedius clones
ST68 and ST71, which harbor mutations within gyrA and grlA
(conferring resistance to fluoroquinolones), as well as a Tn5404-
like transposon element that harbors the dfrG (sulfamethoxazole
resistance) and ermB (clindamycin and erythromycin resistance)
genes (4). Interestingly, differences were noted in our collection
based on the SCCmec type. Isolates with SCCmec V were more
commonly resistant to erythromycin and clindamycin (10/11 iso-
lates, 90.9%), SXT (10/11 isolates, 90.9%), doxycycline (8/11 iso-
lates, 72.7%), and ciprofloxacin (9/11 isolates, 81.8%) than those
with SCCmec types IV or III. For SCCmec type IV, 4 of 8 (50.0%),
8 of 8 (100%), 1 of 8 (12.5%), and 0 of 8 (0.0%) isolates were
resistant to these antimicrobials, respectively. For isolates with
SCCmec type III, 4 of 9 (44.4%), 2 of 9 (22.2%), 4 of 9 (44.4%), and
0 of 9 (0.0%) were resistant. Isolates of theMDRNorth American
ST68 lineage harbor SCCmec V, similar to the more resistant iso-
lates in our collection (4).
Doxycycline susceptibility was 89.7% among mecA-negative
isolates and only 51.4% among mecA-positive isolates (Table 1).
This was in striking contrast to doxycycline susceptibility rates
among human isolates of methicillin-resistant S. aureus (MRSA),
which were 96% among a collection of4,000 isolates recovered
from human diagnostic specimens in 2010 (12). Doxycycline sus-
ceptibility rates were similarly high among methicillin-resistant
coagulase-negative Staphylococci (CoNS), at 94.1% in one study of
1,473 isolates (13). Our data are consistent with previous studies
that documented 31% to 38% doxycycline susceptibility among
methicillin-resistant S. pseudintermedius (MRSP) isolates from
canine sources (14, 15). No difference was found in susceptibility
to doxycycline between human (n  5, 40.0% susceptible) and
TABLE 1 MIC values of 15 antimicrobial agents for Staphylococcus intermedius group (n 115) when tested by the CLSI reference broth
microdilution MIC method in cation-adjusted Mueller-Hinton broth
Antimicrobial agenta
Number of isolates at MIC (g/ml) ofb: Percent of isolates susceptible
0.06 0.12 0.25 0.5 1 2 4 8 16 32 Human Animal mecA mecA All
Ceftaroline 115c 100 100 100 100 100
Ciprofloxacin 94c 1 20d 91.1 77.1 97.4 51.4 82.6
Clindamycin 78c 1 36d 80.0 60.0 85.9 29.7 67.8
Daptomycin 115c 100 100 100 100 100
Doxycycline 69 20 23 3d 84.4 72.9 89.7 51.4 77.4
Erythromycin 78c 37d 80.0 60.0 85.9 29.7 67.8
Linezolid 1c 63 50 1 100 100 100 100 100
Nitrofurantoin 114 1 100 100 100 100 100
Oxacillin 77c 3e 6 2 1 2 24d 91.1 51.4 98.7 0 66.9
Penicillin 28 5 3 1 2 76d 26.6f 21.4f 50 0 23.5f
QDA 115c 100 100 100 100 100
Rifampin 115c 100 100 100 100 100
SXT 54c 25 1 4 31d 84.4 60.0 92.3 21.6 69.6
Tigecycline 115c 100 100 100 100 100
Vancomycin 14c 100 1 100 100 100 100 100
a QDA, quinupristin-dalfopristin; SXT, trimethoprim-sulfamethoxazole.
b MIC values in the unshaded part of the table fall in the susceptible interpretive category; those in the shaded parts of the table are in the intermediate and/or resistant category.
c MIC less than or equal to value in column header.
d Value greater than or equal to value in column header.
e Includes 1 isolate that was mecA negative.
f Includes 5 human isolates and 1 animal isolate that had penicillin-susceptible MICs but were -lactamase positive.
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veterinary (n 32, 53.1% susceptible) MRSP isolates in the pres-
ent study.
Of note, canine-specific breakpoints for doxycycline have been
proposed to accommodate the pharmacokinetics of doxycycline
doses used for dogs. The canine breakpoints are 0.125 g/ml
(susceptible), 0.25 g/ml (intermediate), and0.5 g/ml (resis-
tant) (16). The lowest concentration of doxycycline tested in our
study was 1 g/ml, so we cannot estimate the effect that these
breakpoints would have on our collection of isolates. However,
35% of mecA-positive and 10.2% of mecA-negative isolates had
MICs of 2 to 4g/ml, which are considered resistant by the canine
breakpoints but susceptible by the human breakpoints. Resistance
to the tetracyclines ismediated through acquisition of tetracycline
resistance genes (tet genes), four of which have been identified
among S. pseudintermedius isolates: tet(M) and tet(O), which me-
diate ribosomal protection, and tet(K) and tet(L), which encode
efflux pumps. The most commonly occurring of these genes are
tet(M) and tet(K) in S. pseudintermedius (16, 17). Isolates that
harbor none of these genes typically have MICs of 0.125
g/ml to doxycycline, whereas acquisition of the tet(M) gene
can be associated with MICs that are elevated but below the
susceptible breakpoint of 4 g/ml given in CLSI document
M100S, 26th edition. Clinically, it is unclear whether isolates
that are susceptible by the CLSI M100S breakpoint and harbor
a tet gene are associated with treatment failures, but these iso-
lates would be considered resistant by the proposed veterinary
breakpoint (16). The EUCAST susceptible breakpoint for doxycy-
cline is1g/ml for human isolates of Staphylococcus spp. (www
.eucast.org), and when applying this breakpoint, only 18.1% of
methicillin-resistant and 79.5% of methicillin-susceptible isolates
in our study would be considered doxycycline susceptible. Re-
gardless, the tet genes are carried on Tn5801 and Tn916 elements
(6), the same as found in human and veterinary isolates of tetra-
cycline-resistant S. aureus (18). The Tn916 tet(M) gene was found
in all isolates of the clonal complex (CC) 398 of S. aureus, suggest-
ing this element was integrated into the genome of the clone early
and disseminated vertically. This may be the case for the ST71 and
ST68 clonal lineages of S. pseudintermedius and may account for
the common occurrence of doxycycline resistance in these iso-
lates. Doxycycline resistance may also be selected for through the
common use of this agent for the treatment of pyoderma in small-
animal veterinary medicine.
SXT susceptibility was only 21.6% among mecA-positive iso-
lates. In contrast, human isolates of MRSA are typically suscepti-
ble to this agent; in 2013, 98.0% of isolates in a collection
of9,000 MRSA isolates were susceptible to SXT (19). SXT sus-
ceptibility is lower among CoNS. In the same study conducted in
2013, 52.7%of 2,268methicillin-resistant CoNS isolates were sus-
ceptible to SXT (19).
All isolates in this study that were resistant to erythromycin
were also resistant to clindamycin, and susceptibility rates for both
agents were only 29.7% among MRSP isolates (Table 1). Conse-
quently, no inducible clindamycin resistance was observed, al-
though an inducible erm gene was previously documented in S.
pseudintermedius (20).
We documented 51.4% ciprofloxacin susceptibility in MRSP
isolates, which was similar to observations in MRSA and MR
CoNS isolates (19). However, this susceptibility rate was signifi-
cantly higher than rates documented in some studies of veterinary
SIG isolates, where susceptibility rates as low as 2.7% were re-
ported using the same susceptible breakpoint of 1 g/ml (21). A
single point mutation in topoisomerase II or IV genes confers
fluoroquinolone resistance in S. pseudintermedius (22).
All isolates were susceptible to ceftaroline, daptomycin, lin-
ezolid, nitrofurantoin, quinupristin-dalfopristin, rifampin, tige-
cycline, and vancomycin. There are currently no vancomycin
breakpoints for SIG, as CLSI only publishes S. aureus and CoNS
breakpoints for this antimicrobial agent. However, unlike for
CoNS, where the modal MIC for vancomycin is 2.0 g/ml, we
found the vancomycin MICmode to be 1.0 g/ml, similar to that
documented for S. aureus. As such, it may be reasonable for clin-
ical laboratories to interpret vancomycinMICs by using the more
conservative S. aureus susceptible breakpoints of 2.0 g/ml
when SIG is encountered, compared to the4-g/ml breakpoint
for CoNS in CLSI M100S or for Staphylococcus spp. in the CLSI
VET01 standards. Similar to other studies of SIG (23), we did not
find any cases of high-level mupirocin resistance among the iso-
lates in this collection, nor did we detect the presence of the
qacA/B gene in any isolates, suggesting the absence of chlorhexi-
dine resistance in these isolates.
In summary, we present in vitro susceptibility results for a large
collection of SIG clinical isolates tested by the CLSI reference
BMD MIC method. Laboratories should carefully review suscep-
tibility results for all coagulase-positive staphylococci and con-
sider using additional identification procedures, such as MALDI-
TOF MS or an automated instrument, for isolates that are
doxycycline and/or SXT resistant, a phenotype common to S.
pseudintermedius but unusual for S. aureus. This is important, as
correct identification of these isolates is critical to accurate testing
of SIG with oxacillin to detect methicillin resistance. Clinicians
should be cognizant of the dramatic difference in SXT, clindamy-
cin, and doxycycline susceptibility between SIG and S. aureus, as
these agents are commonly prescribed as empirical therapy for
MRSA in wound and skin structure infections. While susceptibil-
ity to these antimicrobials was higher in human than in animal
isolates overall (Table 1), this was likely due to the significantly
higher proportion of mecA-positive isolates in the veterinary col-
lection, a bias of our data set. A second limitation of the present
study was the inclusion of only 4 S. delphini and no S. intermedius
isolates; further data will determine if susceptibility rates differ
significantly between these isolates and S. pseudintermedius. It is
worth noting, however, that S. intermedius is rarely isolated in
veterinary or human clinical laboratories but rather is a constitu-
ent of the normal nares flora of the wild pigeon (24).
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